Changing Features of Liver Injury in COVID-19 Patients: Impact of Infection with the SARS-CoV-2 Delta (B.1.617.2) Variants
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: There is growing evidence that abnormal liver function tests (LFTs) are common in patients with coronavirus disease 2019 (COVID-19). However, it is not known whether viral involvement in the liver differs according to the strain. We investigated the impact on liver injury in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta (B.1.617.2) variants. Materials and methods: We conducted a single-center, retrospective cohort study, including 372 patients admitted during the pre-Delta period (PDP: between February 1 and November 30, 2020) and 137 patients admitted during the Delta period (DP: between August 1 and August 31, 2021). Initial liver injury was defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels ≥3 × the upper limit of normal (ULN) or alkaline phosphatase (ALP) or total bilirubin ≥2 × the ULN within 3 days from admission. Results: Of 509 patients with COVID-19 included in our study, 38 (7.5%) patients had initial liver injury. The DP group had a significantly higher rate of initial liver injury than the PDP group (PDP: 5.9% vs. DP: 11.7%, P = 0.028). The DP group (adjusted odds ratio [aOR]: 2.737, 95% confidence interval [CI]: 1.322 - 5.666) was independently associated with initial liver injury. During hospitalization, 160 (31.4%) patients had severe COVID-19. The DP group and initial liver injury had higher odds of progressing to severe COVID-19 (aOR: 2.664, 95% CI: 1.526 - 4.648, and aOR: 4.409, 95% CI: 1.816 - 10.707, respectively). The mediation analysis suggested that initial liver injury mediates the relationship between SARS-CoV-2 Delta variant infection and severe COVID-19 (unstandardized beta coefficient = 0.980, Standard error = 0.284, P = 0.001). Conclusion: Initial liver injury is more common in COVID-19 patients with Delta variants. Also, Delta variants and initial liver injury are associated with poor clinical outcomes.
Abstract
Background: There is growing evidence that abnormal liver function tests (LFTs) are common in patients with coronavirus disease 2019 (COVID-19). However, it is not known whether viral involvement in the liver differs according to the strain. We investigated the impact on liver injury in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta (B.1.617.2) variants. Materials and methods: We conducted a single-center, retrospective cohort study, including 372 patients admitted during the pre-Delta period (PDP: between February 1 and November 30, 2020) and 137 patients admitted during the Delta period (DP: between August 1 and August 31, 2021). Initial liver injury was defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels ≥3 × the upper limit of normal (ULN) or alkaline phosphatase (ALP) or total bilirubin ≥2 × the ULN within 3 days from admission. Results: Of 509 patients with COVID-19 included in our study, 38 (7.5%) patients had initial liver injury. The DP group had a significantly higher rate of initial liver injury than the PDP group (PDP: 5.9% vs. DP: 11.7%, P = 0.028). The DP group (adjusted odds ratio [aOR]: 2.737, 95% confidence interval [CI]: 1.322 - 5.666) was independently associated with initial liver injury. During hospitalization, 160 (31.4%) patients had severe COVID-19. The DP group and initial liver injury had higher odds of progressing to severe COVID-19 (aOR: 2.664, 95% CI: 1.526 - 4.648, and aOR: 4.409, 95% CI: 1.816 - 10.707, respectively). The mediation analysis suggested that initial liver injury mediates the relationship between SARS-CoV-2 Delta variant infection and severe COVID-19 (unstandardized beta coefficient = 0.980, Standard error = 0.284, P = 0.001). Conclusion: Initial liver injury is more common in COVID-19 patients with Delta variants. Also, Delta variants and initial liver injury are associated with poor clinical outcomes.
참고문헌 (37)
- Cucinotta D, "WHO declares COVID-19 a pandemic", Acta Biomed, 91, pp.157~160 (2020)
- Chams N, "COVID-19 : A multidisciplinary review", Front Public Health, 8, pp.383~ (2020)
- Saviano A, "Liver disease and coronavirus disease 2019 : from pathogenesis to clinical care", Hepatology, 74, pp.1088~1100 (2021)
- Sun J, "COVID-19 and liver disease", Liver Int, 40, pp.1278~1281 (2020)
- Guan WJ, "Clinical characteristics of coronavirus disease 2019 in China", N Engl J Med, 382, pp.1708~1720 (2020)
- Phipps MM, "Acute liver injury in COVID-19 : Prevalence and association with clinical outcomes in a large U. S. cohort", Hepatology, 72, pp.807~817 (2020)
- Yip TC, "Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19", Gut, 70, pp.733~742 (2021)
- Lee SY, "Epidemiologic trends in cancer-related emergency department utilization in Korea from 2015 to 2019", Sci Rep, 11, pp.21981~ (2021)
- Ong SWX, "Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2)Variants of Concern : A Retrospective Cohort Study Comparing B. 1. 1. 7(Alpha), B. 1. 351(Beta), and B. 1. 617. 2(Delta)", Clin Infect Dis, 75, pp.e1128~e1136 (2022)
- "South Korea’s New Strategy against Omicron"[URL]
- Shiehzadegan S, "Analysis of the delta variant B. 1. 617. 2 COVID-19", Clin Pract, 11, pp.778~784 (2021)
- Sung Ho Kyung, "Clinical Course and Outcomes of 3,060 Patients with Coronavirus Disease 2019 in Korea, January–May 2020", Journal of Korean Medical Science, 35(30), pp.1~11 (2020), 대한의학회[DOI]
- Kalil AC, "Baricitinib plus remdesivir for hospitalized adults with Covid-19", N Engl J Med, 384, pp.795~807 (2021)
- "Therapeutic management of hospitalized adults with COVID-19"[URL]
- Coltart CEM, "Future developments in the prevention, diagnosis and treatment of COVID-19", Best Pract Res Clin Obstet Gynaecol, 73, pp.56~80 (2021)
- Parasher A, "COVID-19 : Current understanding of its pathophysiology, clinical presentation and treatment", Postgrad Med J, 97, pp.312~320 (2021)
- Chow WS, "How has the extent of institutional mental healthcare changed in Western Europe? Analysis of data since 1990", BMJ Open, 6, pp.e010188~ (2016)
- Ryu Byung-Han, "Clinical Features of Adult COVID-19 Patients without Risk Factors before and after the Nationwide SARS-CoV-2 B.1.617.2 (Delta)-variant Outbreak in Korea: Experience from Gyeongsangnam-do", Journal of Korean Medical Science, 36(49), pp.1~9 (2021), 대한의학회[DOI]
- Ding ZY, "Association of liver abnormalities with in-hospital mortality in patients with COVID-19", J Hepatol, 74, pp.1295~1302 (2021)
- Song Jeong Eun, "Multicenter Analysis of Clinical Features and Prognosis of COVID-19 Patients with Hepatic Impairment", Gut and Liver, 15(4), pp.606~615 (2021), 거트앤리버 소화기연관학회협의회[DOI]
- Nagpal P, "Imaging of COVID-19pneumonia : Patterns, pathogenesis, and advances", Br J Radiol, 93, pp.20200538~ (2020)
- Chakraborty RK, "StatPearls" (2022), StatPearls Publishing
- Baron RM, "The moderator-mediator variable distinction in social psychological research : conceptual, strategic, and statistical considerations", J Pers Soc Psychol, 51, pp.1173~1182 (1986)
- Meltem Agca, "Is Obesity a Potential Risk factor for Poor Prognosis of COVID-19?", Infection and Chemotherapy, 53(2), pp.319~331 (2021), 대한감염학회[DOI]
- Kılınç Gökhan, "Evaluation of Patients Treated in Intensıve Care Due to COVID-19: A Retrospective Study", Infection and Chemotherapy, 54(2), pp.328~339 (2022), 대한감염학회[DOI]
- Huang J, "Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity", J Med Virol, 92, pp.2152~2158 (2020)
- Fisman DN, "Evaluation of the relative virulence of novel SARS-CoV-2 variants : a retrospective cohort study in Ontario, Canada", CMAJ, 193, pp.E1619~25 (2021)
- Hu K, "risk factors for severe cases of the Delta variant", Aging(Albany NY), 13, pp.23459~23470 (2021)
- Mishra K, "Liver injury as a surrogate for inflammation and predictor of outcomes in COVID-19", Hepatol Commun, 5, pp.24~32 (2020)
- Wong GL, "SARS-CoV-2 viral persistence based on cycle threshold value and liver injury in patients with COVID-19", Open Forum Infect Dis, 8, pp.ofab205~ (2021)
- Teyssou E, "The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients", J Infect, 83, pp.e1~3 (2021)
- Wang Y, "Kinetics of viral load and antibody response in relation to COVID-19 severity", J Clin Invest, 130, pp.5235~5244 (2020)
- Kim Min-Kyung, "Clinical Characteristics of 40 Patients Infected With the SARS-CoV-2 Omicron Variant in Korea", Journal of Korean Medical Science, 37(3), pp.1~5 (2022), 대한의학회[DOI]
- Nealon J, "Omicron severity : milder but not mild", Lancet, 399, pp.412~413 (2022)
- Deng H, "Clinical features and predictive factors related to liver injury in SARS-CoV-2 Delta and Omicron variant-infected patients", Eur J Gastroenterol Hepatol, 34, pp.933~939 (2022)
- Ong SWX, "Clinical and virological features of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)variants of concern : A retrospective cohort study comparing B. 1. 1. 7(Alpha), B. 1. 351(Beta), and B. 1. 617. 2(Delta)", Clin Infect Dis, 75, pp.e1128~e1136 (2022)
- Long B, "Clinical update on COVID-19for the emergency clinician : Presentation and evaluation", Am J Emerg Med, 54, pp.46~57 (2022)